✦ LIBER ✦

Cost-Effectiveness Analysis of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Infection in High-Risk Late Preterm Infants in the Netherlands

✍ Scribed by Langenfeld, M.K.; Visser, S.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness Of Prophylaxis Of Res

✍ Rosselli, D.; Rueda, J.D.; Ruiz, J.G. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Palivizumab for respiratory syncytial vi

✍ Jennifer H. Lofland; Suzanne M. Touch; John P. O'Connor; Mary Lou Chatterton; El 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 890 KB

Cost-effectiveness analysis of palivizum

✍ Kristian Neovius; Katharina Buesch; Kristina Sandström; Martin Neovius 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB

PIN35 COST-EFFECTIVENESS ANALYSIS OF PAL

✍ S Ikeda; M Kobayashi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

A cost-effectiveness analysis of respira

✍ Anthony Bentley,Ivana Filipovic,Katherine Gooch… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 597 KB

PIN24 COST-EFFECTIVENESS OF RESPIRATORY

✍ L.B. Weiner; M.J. Polak; A. Masaquel; P.J. Mahadevia 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB